Porcilis PCV M Hyo
porcine circovirus type 2 ORF2 subunit antigen / Mycoplasma hyopneumoniae inactivated
Table of contents
Overview
An overview of Porcilis PCV M Hyo and why it is authorised in the EU
Porcilis PCV M Hyo is a veterinary vaccine used to protect pigs against two separate infections, caused by porcine circovirus and Mycoplasma hyopneumoniae.
- Porcine circovirus type 2 (PCV2) infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
- Infection with the bacterium Mycoplasma hyopneumoniae in pigs causes a disease of the airways called enzootic pneumonia. Affected pigs often have a cough and fail to thrive.
Porcilis PCV M Hyo contains porcine circovirus type 2 (PCV2) subunit antigen (a protein derived from part of the virus) and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria.
Authorisation details
Product details | |
---|---|
Name |
Porcilis PCV M Hyo
|
Agency product number |
EMEA/V/C/003796
|
Active substance |
Porcine circovirus type 2 (PCV2) ORF2 subunit antigen, Mycoplasma hyopneumoniae J strain inactivated
|
International non-proprietary name (INN) or common name |
|
Species |
Pigs (for fattening)
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AL08
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International B.V.
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
06/11/2014
|
Contact address |
Wim de Körverstraat 35 |
Product information
15/06/2020 Porcilis PCV M Hyo - EMEA/V/C/003796 - IA/0014
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for suidae
-
Inactivated viral and inactivated bacterial vaccines
Therapeutic indication
For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. To reduce the loss of daily weight gain during the finishing period in face of infections with Mycoplasma hyopneumoniae and/or PCV2 (as observed in field studies)